Top 5 Best-Selling Respiratory Disease Drugs to Watch in 2025

As respiratory diseases continue to pose a global health burden, 2025 is shaping up to be a pivotal year for lung disease therapeutics.

From breakthrough biologics targeting chronic obstructive pulmonary disease (COPD) to first-in-class drugs for pulmonary arterial hypertension (PAH) and novel anti-inflammatory inhalants, the respiratory drug market is seeing renewed innovation and expanding indications.

In this blog, we explore the top five best-selling lung and respiratory disease drugs that are making waves in 2025, highlighting their clinical impact, market performance and future potential.

When it comes to companies that report in foreign currencies, the conversion to US dollars uses the average annual exchange rates reported by the US Federal Reserve.

1. Dupixent (dupilumab)

Indication(s): Type 2 inflammatory diseases (including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis and chronic spontaneous urticaria) and eosinophilic COPD in markets such as the US, European Union (EU) and Japan.

Manufacturer(s): Sanofi/Regeneron

2024 Sales (USD): $14.15 billion

2025 Outlook: In 2024, Regeneron reported $14.15 billion in global Dupixent sales, a 22 % increase from 2023. According to Sanofi, the dual IL-4/IL-13 inhibitor brought in €3.46 billion in Q4 alone (+16 %). US revenue climbed about 10% to €2.55 billion in Q4. Sales were strong in the US, Europe and emerging markets like China and Japan. The drug’s expansion into COPD, a market historically underserved by biologics, is seen as a game-changer, with analysts forecasting that peak sales could eventually exceed $20 billion annually. Backed by strong efficacy in reducing exacerbations and hospitalizations in eosinophilic COPD patients, Dupixent is expected to gain significant traction in 2025 as prescriber familiarity and payer coverage grow.

2. Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor)

Indication(s): Cystic fibrosis

Manufacturer(s): Vertex Pharmaceuticals Inc.

2024 Sales (USD): $10.24 billion

2025 Outlook: Trikafta remains Vertex’s powerhouse, generating approximately $2.53 billion in Q1 2024 sales, up 2% year-over-year, and playing a key role in a 13% uplift in quarterly cystic fibrosis product revenue to $2.69 billion. The company reported total product revenues of $11.02 billion for the year, a 12% increase from 2023, with Trikafta/Kaftrio accounting for the majority of sales at $10.24 billion. The FDA also broadened its approval to include children aged two and older with F508del and other responsive CFTR mutations, opening access to around 300,000 more patients in the US. Trikafta/Kaftrio’s widespread success stems from its transformative clinical impact as it’s effective in approximately 90% of cystic fibrosis patients, particularly those with at least one F508del mutation, and has been shown to markedly improve lung function and overall quality of life. Its broad eligibility and substantial clinical benefit have established it as the standard of care in many countries. Vertex has capitalized on its market exclusivity, maintaining a high US annual price of around $300,000 per patient. Trikafta has been approved in over 60 countries and in 2024, struck several pricing and access deals, including an agreement with the UK’s National Institute for Health and Care Excellence (NICE) that extended coverage to more patients. As Vertex further penetrates pediatric markets and explores rare mutations, Trikafta’s combination of sustained blockbuster sales and growing patient coverage makes it a critical growth driver in 2025.

3. Xolair (omalizumab)

Indication(s):  Moderate-to-severe allergic asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, IgE-mediated food allergies.

Manufacturer(s): Roche/Novartis

2024 Sales (USD): $4.45 billion

2025 Outlook: Roche reported global sales of approximately CHF 2.47 billion ($2.80 billion USD) for Xolair in 2024, marking a 16% year-over-year increase. Xolair holds multiple indications, including a recent, first-in-class IgE-mediated food allergy approval, and sustained growth in respiratory and immunologic markets, which has helped drive broader uptake of Xolair. The food allergies approval has opened access to a vast, underserved patient population, including children as young as one year old. The landmark label expansion is expected to significantly grow the eligible treatment pool, with analysts projecting peak sales from the food allergy indication alone to eventually exceed $1 billion annually. Additionally, Xolair’s strong clinical legacy and favorable safety profile have made it a trusted brand among allergists and immunologists, supporting continued growth across its original indications. With rising global demand and expanding use cases, Xolair is poised for another high-growth year in 2025.

4. Ofev (nintedanib)

Indication(s): Idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.

Manufacturer(s): Boehringer Ingelheim

2024 Sales (USD): $4.07 billion

2025 Outlook: Ofev is positioned as a key respiratory drug to watch in 2025, driven by strong financial performance and a broad clinical footprint. In 2024, Boehringer Ingelheim reported €3.77 billion ($4.07 billion) in Ofev sales, representing 8.9% growth at constant exchange rates, making it one of the company’s top revenue drivers. Boehringer also noted that its total treated patient population rose by 8% in 2024, reaching 66 million people, largely due to continued uptake of Ofev in ILD markets. The treatment has broad applicability across multiple fibrotic lung conditions, including IPF and other chronic fibrosing ILDs. As the company prepares for upcoming patent expirations, it is investing in next-generation antifibrotic therapies, like nerandomilast, reinforcing Ofev’s importance as a growth engine heading into 2025.

5. Trelegy Ellipta (fluticasone/umeclidinium/vilanterol)

Indication(s): COPD, asthma

Manufacturer(s): GSK

2024 Sales (USD): $3.45 billion

2025 Outlook: Trelegy Ellipta is set to be a respiratory drug to watch in 2025, fueled by exceptional 2024 performance and clinical momentum. The inhaled triple-combination therapy — approved for the maintenance treatment of both COPD and asthma in adults — is now the most-prescribed single-inhaler triple therapy globally, with full-year sales growing an impressive 27% to approximately £2.7 billion (~$3.45 billion). This growth was driven by strong volume uptake across all regions, supported by effective pricing strategies, particularly in the US. As guidelines increasingly favor single-inhaler triple therapy for moderate to severe cases, Trelegy’s market share is expected to expand further, benefiting from seamless once‑daily dosing and high patient adherence. With a growing global COPD/asthma market projected to reach over $16 billion by 2032 at a compound annual growth rate ( of 8.45%, Trelegy’s strong positioning, ongoing guideline support and label breadth underscore its continued dominance in 2025.